NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free NGNE Stock Alerts $29.96 +0.09 (+0.30%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$29.88▼$31.5250-Day Range$29.46▼$50.9052-Week Range$12.20▼$53.00Volume47,839 shsAverage Volume125,821 shsMarket Capitalization$384.99 millionP/E RatioN/ADividend YieldN/APrice Target$49.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Neurogene alerts: Email Address Neurogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.6% Upside$49.00 Price TargetShort InterestBearish8.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.77) to ($3.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.97 out of 5 starsMedical Sector799th out of 916 stocksPharmaceutical Preparations Industry370th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.58% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Neurogene has recently increased by 9.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NGNE. Previous Next 0.8 News and Social Media Coverage News SentimentNeurogene has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Neurogene this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for NGNE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.58% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($6.77) to ($3.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Neurogene Stock (NASDAQ:NGNE)Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More NGNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGNE Stock News HeadlinesApril 22, 2024 | businesswire.comNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingApril 20, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Neurogene Inc. (NASDAQ:NGNE) Lowered by William BlairApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 26, 2024 | seekingalpha.comNeurogene Stock: Gene Therapy Specialist May Break Chain Of Failed MergersMarch 20, 2024 | finance.yahoo.comNeurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023March 19, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)March 19, 2024 | finance.yahoo.comWith 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investorsMarch 18, 2024 | businesswire.comNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 5, 2024 | edition.cnn.comAkero Therapeutics, Inc.March 4, 2024 | finance.yahoo.comNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialMarch 1, 2024 | finance.yahoo.comNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerMarch 1, 2024 | finance.yahoo.comNeurogene to Participate in Upcoming Investor ConferencesSee More Headlines Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CUSIPN/A CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees91Year FoundedN/APrice Target and Rating Average Stock Price Target$49.00 High Stock Price Target$61.00 Low Stock Price Target$31.00 Potential Upside/Downside+63.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($12.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.17% Return on Assets-26.08% Debt Debt-to-Equity RatioN/A Current Ratio8.72 Quick Ratio8.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book2.06Miscellaneous Outstanding Shares12,850,000Free Float12,650,000Market Cap$384.99 million OptionableNo Data Beta1.26 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Rachel L. McMinn Ph.D. (Age 51)Founder, CEO & Director Ms. Christine Mikail Cvijic J.D. (Age 46)President, CFO & Secretary Mr. Arvind SreedharanSenior Vice President of Business OperationsDr. Stuart Cobb Ph.D.Chief Scientific OfficerMs. Donna M. Cochener-Metcalfe J.D. (Age 48)Senior Vice President & General Counsel Dr. Effie Albanis M.D.Senior Vice President of Early Clinical & Translational ResearchDr. Andrew E. Mulberg CPIFAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality ControlMr. Ricardo JimenezSenior Vice President of Technical OperationsDr. Albena Patroneva M.B.A. (Age 59)M.D., Senior Vice President of Clinical Development Dr. Julie Jordan M.D. (Age 51)Chief Medical Officer More ExecutivesKey CompetitorsOrganogenesisNASDAQ:ORGOHeron TherapeuticsNASDAQ:HRTXBiomea FusionNASDAQ:BMEAADC TherapeuticsNYSE:ADCTCorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInstitutional OwnershipGreat Point Partners LLCBought 994,229 shares on 2/15/2024Ownership: 42.326%Avidity Partners Management LPBought 466,243 shares on 2/14/2024Ownership: 19.840%BML Capital Management LLCBought 24,666 shares on 2/2/2024Ownership: 1.050%View All Institutional Transactions NGNE Stock Analysis - Frequently Asked Questions Should I buy or sell Neurogene stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurogene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NGNE shares. View NGNE analyst ratings or view top-rated stocks. What is Neurogene's stock price target for 2024? 4 equities research analysts have issued 1-year price targets for Neurogene's shares. Their NGNE share price targets range from $31.00 to $61.00. On average, they expect the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts price targets for NGNE or view top-rated stocks among Wall Street analysts. How have NGNE shares performed in 2024? Neurogene's stock was trading at $19.38 at the beginning of 2024. Since then, NGNE stock has increased by 54.6% and is now trading at $29.96. View the best growth stocks for 2024 here. Are investors shorting Neurogene? Neurogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 906,000 shares, an increase of 130.4% from the March 15th total of 393,200 shares. Based on an average trading volume of 135,600 shares, the short-interest ratio is presently 6.7 days. Currently, 7.9% of the company's stock are sold short. View Neurogene's Short Interest. When is Neurogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our NGNE earnings forecast. What ETF holds Neurogene's stock? Invesco DWA SmallCap Momentum ETF holds 124,536 shares of NGNE stock, representing 0.49% of its portfolio. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGNE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
